PARP Inhibitors

PARP

PARP1

PARP2

PARP3

PARP4

TNKS1/PARP5A

TNKS2/PARP5B

PARP7

PARP10

PARP14

PARP15

PARP12

PARP16

PARP Inducers, Degraders, Inhibitors & Activators

Product Name	PARP	PARP1	PARP2	PARP3	PARP4	TNKS1/PARP5A	TNKS2/PARP5B	PARP7	PARP10	PARP14	PARP15	PARP12	PARP16	Purity
Olaparib		PARP-1, IC₅₀: 5 nM	PARP-2, IC₅₀: 1 nM			tankyrase-1, IC₅₀: 1.5 μM								99.98%
XAV-939		ARTD1, IC₅₀: 5500 nM	ARTD2, IC₅₀: 479 nM			TNKS1, IC₅₀: 5 nM	TNKS2, IC₅₀: 2 nM							99.91%
Talazoparib		PARP1, Ki: 1.2 nM	PARP2, Ki: 0.87 nM											99.89%
Niraparib		PARP-1, IC₅₀: 3.8 nM	PARP-2, IC₅₀: 2.1 nM	PARP-3, IC₅₀: 1300 nM	V-PARP, IC₅₀: 330 nM	TANK-1, IC₅₀: 570 nM								99.96%
Saruparib		PARP1, IC₅₀: 3 nM	PARP2, IC₅₀: 1400 nM											99.76%
IRF1-IN-1		PARP-1												99.72%
IRF1-IN-2		PARP-1												99.83%
PARP1/CDK12-IN-1		PARP1, IC₅₀: 34 nM
Rucaparib		PARP-1, Ki: 1.4 nM												99.97%
Chlorin e6		PARP-1												98.38%
Veliparib		PARP-1, Ki: 5.2 nM	PARP-2, Ki: 2.9 nM											99.78%
PJ34	PARP, IC₅₀: 110 nM	PARP-1, IC₅₀: 110 nM	PARP-2, IC₅₀: 86 nM											98.11%
KSQ-4279		PARP1												99.95%
RBN-2397								PARP-7, IC₅₀: 3 nM PARP-7, Kd: 1 nM						99.86%
Pamiparib	PARP													99.97%
Fluzoparib		PARP-1, IC₅₀: 1.46±0.72 nM												99.96%
RBN012759					PARP4, IC₅₀: 10 μM			PARP7, IC₅₀: 4 μM	PARP10, IC₅₀: 1 μM	PARP14, IC₅₀: <3 nM				99.80%
Dehydrocorydaline	PARP													99.77%
SK-575		PARP1, IC₅₀: 2.30 nM												99.86%
Niraparib hydrochloride		PARP-1, IC₅₀: 3.8 nM	PARP-2, IC₅₀: 2.1 nM	PARP-3, IC₅₀: 1300 nM	V-PARP, IC₅₀: 330 nM	TANK-1, IC₅₀: 570 nM								99.41%
Rucaparib phosphate		PARP-1, Ki: 1.4 nM												99.76%
Niraparib tosylate		PARP-1, IC₅₀: 3.8 nM	PARP-2, IC₅₀: 2.1 nM	PARP-3, IC₅₀: 1300 nM	V-PARP, IC₅₀: 330 nM	TANK-1, IC₅₀: 570 nM								99.99%
3-Aminobenzamide	PARP, IC₅₀: 50 nM													99.99%
NVP-TNKS656			PARP2, IC₅₀: 32 μM				TNKS2, IC₅₀: 6 nM							99.66%
AG14361		PARP-1, Ki: 0.5 nM												99.44%
WIKI4							TNKS2, IC₅₀: 26 nM							99.93%
G007-LK						TNKS1, IC₅₀: 46 nM	TNKS2, IC₅₀: 25 nM							99.24%
Peiminine		PARP-1												99.94%
Paris saponin VII		PARP-1												99.96%
Stenoparib		PARP1, IC₅₀: 2 nM	PARP2, IC₅₀: 1 nM			TNKS1, IC₅₀: 50 nM	TNKS2, IC₅₀: 50 nM							≥98.0%
Rucaparib (monocamsylate)		PARP-1, Ki: 1.4 nM												99.82%
BGP-15	PARP, IC₅₀: 120 μM													≥98.0%
Triclabendazole	PARP													99.36%
DPQ		PARP-1												99.68%
AZD-2461		PARP1, IC₅₀: 5 nM	PARP2, IC₅₀: 2 nM	PARP3, IC₅₀: 200 nM										99.79%
OUL232		PARP1, IC₅₀: 15 μM	PARP2, IC₅₀: 10 μM	PARP3, IC₅₀: 50 μM	PARP4, IC₅₀: 11 μM	TNKS1, IC₅₀: 5.4 μM	TNKS2, IC₅₀: 10 μM	PARP7, IC₅₀: 83 nM	PARP10, IC₅₀: 7.8 nM	PARP14, IC₅₀: 300 nM	PARP15, IC₅₀: 56 nM			99.86%
PJ34 hydrochloride	PARP, IC₅₀: 110 nM	PARP-1, IC₅₀: 110 nM	PARP-2, IC₅₀: 86 nM											99.91%
RBN-3143		PARP1, IC₅₀: >100000 nM	PARP2, IC₅₀: >100000 nM	PARP3, IC₅₀: >100000 nM	PARP4, IC₅₀: 42700 nM				PARP10, IC₅₀: 1600 nM	PARP14, IC₅₀: 4 nM	PARP15, IC₅₀: 4200 nM			99.24%
OUL35									ARTD10/PARP10, IC₅₀: 329 nM					99.80%
UPF 1069		PARP-1, IC₅₀: 8 μM	PARP-2, IC₅₀: 0.3 μM											99.02%
DB008													PARP16, IC₅₀: 0.27 μM	98.78%
Veliparib dihydrochloride		PARP-1, Ki: 5.2 nM	PARP-2, Ki: 2.9 nM											99.98%
iRucaparib-AP6		PARP1, DC₅₀: 82 nM												99.27%
ME0328		ARTD1/PARP1, IC₅₀: 6.3 μM	ARTD2/PARP2, IC₅₀: 10.8 μM	ARTD3/PARP3, IC₅₀: 0.89 μM		ARTD5/TNKS1, IC₅₀: 47.3 μM	ARTD6/TNKS2, IC₅₀: 34.3 μM		ARTD10/PARP10, IC₅₀: 71.3 μM					99.64%
RK-287107						tankyrase-1, IC₅₀: 14.3 nM	tankyrase-2, IC₅₀: 10.6 nM							99.80%
Venadaparib		PARP1, IC₅₀: 1.4 nM	PARP2, IC₅₀: 1 nM											98.11%
AZ6102		PARP1, IC₅₀: 2 μM	PARP2, IC₅₀: 0.5 μM			TNKS1, IC₅₀: 3 nM	TNKS2, IC₅₀: 2 nM							99.65%
1,5-Isoquinolinediol	PARP, IC₅₀: 0.18-0.37 μM													99.18%
Iniparib		PARP1												99.74%
5,7,4'-Trimethoxyflavone	PARP													99.65%
JW 55						TNKS1, IC₅₀: 1.9 μM	TNKS2, IC₅₀: 0.83 μM							99.83%
MN-64		ARTD1, IC₅₀: 19.1 μM	ARTD2, IC₅₀: 39.4 μM			TNKS1, IC₅₀: 6 nM	TNKS2, IC₅₀: 72 nM							99.61%
OM-153						TNKS1, IC₅₀: 13 nM	TNKS2, IC₅₀: 2 nM							99.59%
N-Descyclopropanecarbaldehyde Olaparib	PARP													99.27%
Gomisin N		PARP-1												99.94%
NMS-P118		PARP-1, Kd: 9 nM	PARP-2, Kd: 1390 nM											99.54%
PARP7-IN-16		PARP-1, IC₅₀: 0.94 nM	PARP-2, IC₅₀: 0.87 nM					PARP-7, IC₅₀: 0.21 nM						99.91%
Nesuparib			PARP2, IC₅₀: 2 nM			tankyrase-1, IC₅₀: 5 nM	tankyrase-2, IC₅₀: 1 nM							99.54%
BYK204165		hPARP-1, pIC₅₀: 7.35	mPARP-2, pIC₅₀: 5.38											98.66%
PARP7-IN-15								PARP7, IC₅₀: 0.56 nM						98.22%
PARP10/15-IN-1									PARP10, IC₅₀: 160 nM		PARP15, IC₅₀: 370 nM
PARP14 inhibitor H10										PARP14, IC₅₀: 490 nM				98.04%
K-756						TNKS1, IC₅₀: 31 nM	TNKS2, IC₅₀: 36 nM							99.25%
ASP3026		PARP1												99.88%
PROTAC PARP1 degrader		PARP1												99.74%
PARP1-IN-5 dihydrochloride		PARP-1, IC₅₀: 14.7 nM	PARP-2, IC₅₀: 0.9 μM
MSC2504877		PARP1, IC₅₀: 0.54 μM												98.50%
API-1	PARP													99.62%
INO-1001	PARP													98.86%
5,7-Dihydroxychromone	PARP													99.94%
Niraparib (R-enantiomer)		PARP-1, IC₅₀: 2.4 nM												99.69%
Simmiparib		PARP1, IC₅₀: 0.74 nM	PARP2, IC₅₀: 0.22 nM											99.01%
PARP10-IN-3		human PARP1, IC₅₀: >100 μM	human PARP2, IC₅₀: 1.7 μM	human PARP3, IC₅₀: >100 μM	human PARP4, IC₅₀: 7 μM	human TNKS1, IC₅₀: 21 μM	human TNKS2, IC₅₀: 6.5 μM		human PARP10, IC₅₀: 480 nM	human PARP14, IC₅₀: 41 μM	human PARP15, IC₅₀: 1.7 μM	human PARP12, IC₅₀: >10 μM	human PARP16, IC₅₀: >10 μM	98.89%
Mefuparib hydrochloride		PARP1, IC₅₀: 3.2 nM	PARP2, IC₅₀: 1.9 nM			TNKS1, IC₅₀: 1.6 μM	TNKS2, IC₅₀: 1.3 μM							98.62%
(8R,9S)-Talazoparib		PARP-1, IC₅₀: 144 nM												98.28%
A-966492		PARP-1, Ki: 1 nM	PARP-2, Ki: 1.5 nM											99.00%
PARP10/15-IN-3									PARP10, IC₅₀: 0.14 μM		PARP15, IC₅₀: 0.40 μM			99.98%
PROTAC PARP1 degrader-1		PARP-1												99.86%
Niraparib tosylate hydrate		PARP-1, IC₅₀: 3.8 nM	PARP-2, IC₅₀: 2.1 nM	PARP-3, IC₅₀: 1300 nM	V-PARP, IC₅₀: 330 nM	TANK-1, IC₅₀: 570 nM								99.97%
7-Methylguanine		PARP-1, Ki: 61 μM												99.97%
PARP-1-IN-3		PARP-1, IC₅₀: 0.25 nM	PARP-2, IC₅₀: 2.34 nM											99.30%
GeA-69										PARP14, Kd: 2.1 μM				99.91%
NMS-P515		PARP-1, Kd: 16 nM PARP-1, IC₅₀: 27 nM (in Hela cells)												98.18%
ART-IN-1			PARP2, IC₅₀: 19 μM				TNKS2, IC₅₀: 22 μM		PARP10, IC₅₀: 2.4 μM	PARP14, IC₅₀: >100 μM	PARP15, IC₅₀: 1.1 μM			98.91%
TIQ-A			PARP2, IC₅₀: 210 nM				TNKS2, IC₅₀: 24 nM		PARP10, IC₅₀: >10 μM	PARP14, IC₅₀: >10 μM	PARP15, IC₅₀: 230 nM			99.85%
PARP7-IN-16 free base		PARP1, IC₅₀: 0.94 nM	PARP2, IC₅₀: 0.87 nM					PARP7, IC₅₀: 0.21 nM						99.40%
PARP-2-IN-1			PARP-2, IC₅₀: 11.5 nM											99.56%
PARP7-IN-22								PARP-7, IC₅₀: 0.6 nM
PARP10/15-IN-2									PARP10, IC₅₀: 0.15 μM		PARP15, IC₅₀: 0.37 μM			99.00%
PARP1-IN-29		PARP-1, IC₅₀: 6.3 nM
PARP-1-IN-2		PARP-1, IC₅₀: 149 ± 11.0 nM												99.48%
YCH1899		PARP-1, IC₅₀: <0.001 nM	PARP-2, IC₅₀: <0.001 nM	PARP3, IC₅₀: 1.1 nM	PARP4, IC₅₀: 1.0 nM	TNKS1, EC₅₀: 3.8 nM	TNKS2, IC₅₀: 12.4 nM	PARP-7, IC₅₀: 7.3 nM	ARTD10/PARP10, IC₅₀: 10.8 nM	PARP14, IC₅₀: 35.914 μM	PARP15, IC₅₀: 51.623 nM	human PARP12, IC₅₀: 14.1 nM		99.39%
DR2313		PARP-1, IC₅₀: 0.20 μM	PARP-2, IC₅₀: 0.24 μM											99.66%
PARP1-IN-11		PARP1, IC₅₀: 0.082 μM												98.58%
PARP7-IN-17								PARP7						99.81%
PARP/PI3K-IN-1		PARP-1, pIC₅₀: 8.22	PARP-2, pIC₅₀: 8.44											99.43%
E7016	PARP													98.46%
KSQ-4279 (gentisate)		PARP1
Anticancer agent 43		PARP1												98.58%
PARP10-IN-2		human PARP1, IC₅₀: >100 μM	human PARP2, IC₅₀: 27 μM	human PARP3, IC₅₀: >100 μM	human PARP4, IC₅₀: >100 μM	human TNKS1, IC₅₀: >100 μM	human TNKS2, IC₅₀: >100 μM		human PARP10, IC₅₀: 3.64 μM	human PARP14, IC₅₀: >100 μM	human PARP15, IC₅₀: 11 μM	human PARP12, IC₅₀: >10 μM	human PARP16, IC₅₀: >10 μM	98.02%
Rucaparib tartrate		PARP-1, Ki: 1.4 nM
Rucaparib camsylate		PARP-1, Ki: 1.4 nM
Venadaparib hydrochloride		PARP1, IC₅₀: 1.4 nM	PARP2, IC₅₀: 1 nM
PARP1-IN-5		PARP-1, IC₅₀: 14.7 nM	PARP-2, IC₅₀: 0.9 μM
Rucaparib hydrochloride		PARP-1, Ki: 1.4 nM
BPA-B9	PARP
Rucaparib acetate		PARP-1, Ki: 1.4 nM
Tankyrase-IN-3						TNKS1, IC₅₀: 22 nM
PARP14 inhibitor 1										PARP14, IC₅₀: 5.52 nM
PARP-2/1-IN-2		PARP1, Ki: 5 nM	PARP2, Ki: 2 nM
PARP1-IN-12		PARP-1, IC₅₀: 2.99 nM
PARP7-IN-24								PARP7
TC-E 5001						TNKS1, Ki: 79 nM	TNKS2, Ki: 28 nM
PARPYnD		PARP1	PARP2
Antitumor agent-170								PARP7, IC₅₀: 7.05 nM
AZ0108		PARP1, IC₅₀: 0.03 μM	PARP2, IC₅₀: 0.03 μM	PARP3, IC₅₀: 2.8 μM		TNKS1, IC₅₀: 3.2 μM
PARP1-IN-20		PARP1, IC₅₀: 4.62 nM
PARP-1/2/7-IN-1		PARP1	PARP2					PARP7
PARP1-IN-18		PARP1, IC₅₀: 2.7 nM
PARP1-IN-30		PARP1
PARP1/BRD4-IN-3		PARP1, IC₅₀: 2019 nM
PARP/EZH2-IN-1		PARP-1, IC₅₀: 6.87 nM
PARP1-IN-35		PARP1, IC₅₀: 0.2 nM	PARP2, IC₅₀: 122 nM
PARP-1/HDAC-IN-1		PARP-1, IC₅₀: 68.90 nM
PARP1-IN-34		PARP1, IC₅₀: 0.32 nM	PARP2, IC₅₀: 326 nM
PROTAC PARP1 degrader-4		PARP1
Tankyrase-IN-4						TNKS1, IC₅₀: 0.8 nM
ZINC20906412									PARP10
PARP1/c-Met-IN-1		PARP1, IC₅₀: 3.3 nM
PARP/EZH2-IN-2		PARP1, IC₅₀: 6.89 ± 0.7 nM
PARP1/2-IN-3		PARP-1, IC₅₀: 0.2235 nM
DPQ hydrochloride		PARP-1
PARP1-IN-33		PARP1, IC₅₀: 0.41 nM												99.87%
PARP1/BRD4-IN-2		PARP1, IC₅₀: 197 nM
PARP-2-IN-3			PARP-2, IC₅₀: 0.07 μM
PARP1-IN-37		PARP1, IC₅₀: 24 nM
PARP14 inhibitor 2										PARP14, IC₅₀: <30 nM
OM-1700						TNKS1, IC₅₀: 127 nM	TNKS2, IC₅₀: 14 nM
PARP1-IN-22		PARP1
PARP1/BRD4-IN-1		PARP1, IC₅₀: 49 nM
PARP7-IN-12								PARP7, IC₅₀: 7.836 nM
Antitumor agent-169								PARP7, IC₅₀: 2.5 nM
PARP1-IN-9		PARP1, IC₅₀: 30.51 nM
PARP1-IN-21		PARP1
ARTD10/PARP10-IN-1		ARTD1/PARP1, IC₅₀: 4.4 μM							ARTD10/PARP10, IC₅₀: 0.8 μM	ARTD8/PARP14, IC₅₀: 1.6 μM	ARTD7/PARP15, IC₅₀: 1.7 μM
PARP7-IN-23								PARP7
SK-575-NEG		PARP-1, IC₅₀: 2.64 nM
ARTD10/PARP10-IN-2		ARTD1/PARP1, IC₅₀: 9.7 μM							ARTD10/PARP10, IC₅₀: 2.0 μM	ARTD8/PARP14, IC₅₀: >20 μM	ARTD7/PARP15, IC₅₀: >20 μM
OUL245		PARP-1, IC₅₀: 570 nM	PARP2, IC₅₀: 44 nM	PARP3, IC₅₀: 8.8 μM	PARP4, IC₅₀: 6.0 μM	TNKS1, IC₅₀: 1.6 μM	TNKS2, IC₅₀: 370 μM		PARP10, IC₅₀: 2.9 μM	PARP14, IC₅₀: 6.7 μM	PARP15, IC₅₀: 2.0 μM
PARP1-IN-10		PARP1, IC₅₀: 50.62 nM (^[1])
(rac)-Talazoparib		PARP1, Ki: 1.2 nM	PARP2, Ki: 0.87 nM
CEP-9722		PARP-1, IC₅₀: 20 nM	PARP-2, IC₅₀: 6 nM
KU-0058948 hydrochloride		PARP-1, IC₅₀: 3.4 nM
PARP1-IN-14		PARP1, IC₅₀: 0.6 ± 0.1 nM
PARP1-IN-8		PARP-1, IC₅₀: 97 nM												99.29%
NDs-IN-1		hPARP-1	PARP-2
PARP1/2/TNKS1/2-IN-1		PARP-1, IC₅₀: 0.25 nM	PARP-2, IC₅₀: 1.2 nM			TNKS1, IC₅₀: 13.5 nM	TNKS2, IC₅₀: 4.15 nM
PARP7-IN-21								PARP7
PARP1-IN-17		PARP-1
TOPOI/PARP-1-IN-2		PARP-1, IC₅₀: 32.2 nM	PARP-2, IC₅₀: 2844 nM
ZINC43120769		PARP1
CDK9/PARP-IN-1		PARP1, IC₅₀: 107 nM
PARP-1-IN-23		PARP-1, IC₅₀: 12.38 nM
KWZY-11		PARP1, IC₅₀: 156.8 nM	PARP2, IC₅₀: 197.3 nM
Anticancer agent 64	PARP
DLC-50		PARP1, IC₅₀: 1.2 nM
PROTAC PARP1 degrader-3		PARP-1, DC₅₀: 58.14 nM
EB-47		ARTD1/PARP1, IC₅₀: 45 nM
ST7710AA1		PARP-1, IC₅₀: 0.07 μM
Benzo[c][1,8]naphthyridin-6(5H)-one		PARP-1, IC₅₀: 0.311 μM
TNKS-IN-3							TNKS2, Ki: 8.5 nM
KU-0058948		PARP-1, IC₅₀: 3.4 nM
EXQ-2d						TNKS1, IC₅₀: 48.8 nM	TNKS2, IC₅₀: 13.8 nM
8-Chloroquinazolin-4-ol		PARP-1, IC₅₀: 5.65 μM												98.44%
UPF-1035		PARP-1, IC₅₀: 9 μM	PARP-2, IC₅₀: 0.15 μM
BSI-401		PARP-1
KU-0058684		PARP-1, IC₅₀: 3.2 nM
WD2000-012547		PARP-1, pKi: 8.221

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4